MCRB News and Press, Seres Therapeutics Inc. From 09/23/25

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Company continues to enga...

2025-09-08 09:04:34 ET More on Seres Therapeutics Seres Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthr...

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview at...

2025-08-06 21:48:01 ET More on Seres Therapeutics Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough Seres Therapeutics GAAP EPS of -$2.27 beats by $0.22 Seekin...

2025-08-06 21:47:31 ET Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Conference Call August 06, 2025, 08:30 AM ET Company Participants Carlo Tanzi - Corporate Participant Investor Relations - Corporate Participant Dennis M. Walling - Senior VP of Clinical Deve...

2025-08-06 07:26:40 ET More on Seres Therapeutics Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough Seeking Alpha’s Quant Rating on Seres Therapeutics Historical earnings data for Seres Therapeutics Financial informat...

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...

Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regard...

Seres Therapeutics Inc. (MCRB) is expected to report $-2.72 for Q2 2025

2025-07-29 14:09:16 ET ... Read the full article on Seeking Alpha For further details see: Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough